先進的治療薬CDMOの世界市場予測(~2027年)

• 英文タイトル:Advanced Therapy Medicinal Products CDMO Market Research Report by Products, Phase, Indication, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Advanced Therapy Medicinal Products CDMO Market Research Report by Products, Phase, Indication, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「先進的治療薬CDMOの世界市場予測(~2027年)」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301B088
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、247ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iリサーチ社では、2021年に5,452.88百万ドルであった世界の先進的治療薬CDMO市場規模が、2022年に6,292.62百万ドルに達し、2027年には年平均成長率15.65%で13,050.03百万ドルまで拡大すると予測しています。本調査レポートは、先進的治療薬CDMOの世界市場を調査対象とし、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(細胞治療、遺伝子治療、組織工学治療)分析、フェーズ別(フェーズI、フェーズII、フェーズIII、フェーズIV)分析、疾患別(循環器、中枢神経、皮膚科、内分泌・代謝・遺伝子、消化器)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容でまとめております。なお、本書に掲載されている企業情報には、Advanced Therapies, Inc.、AGC Inc.、Almac Group、Arranta Bio、Bio Elpida、Catalent Inc.、Cell and Gene Therapy Catapult Limited、Celonic AG、Charles River Laboratories、Cobra Biologics Limited、Coriolis Pharma Research GmbHなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト

・世界の先進的治療薬CDMO市場規模:製品別
- 細胞治療の市場規模
- 遺伝子治療の市場規模
- 組織工学治療の市場規模

・世界の先進的治療薬CDMO市場規模:フェーズ別
- フェーズIにおける市場規模
- フェーズIIにおける市場規模
- フェーズIIIにおける市場規模
- フェーズIVにおける市場規模

・世界の先進的治療薬CDMO市場規模:疾患別
- 循環器疾患における市場規模
- 中枢神経疾患における市場規模
- 皮膚疾患における市場規模
- 内分泌・代謝・遺伝子疾患における市場規模
- 消化器疾患における市場規模

・世界の先進的治療薬CDMO市場規模:地域別
- 南北アメリカの先進的治療薬CDMO市場規模
アメリカの先進的治療薬CDMO市場規模
カナダの先進的治療薬CDMO市場規模
ブラジルの先進的治療薬CDMO市場規模

- アジア太平洋の先進的治療薬CDMO市場規模
日本の先進的治療薬CDMO市場規模
中国の先進的治療薬CDMO市場規模
インドの先進的治療薬CDMO市場規模
韓国の先進的治療薬CDMO市場規模
台湾の先進的治療薬CDMO市場規模

- ヨーロッパ/中東/アフリカの先進的治療薬CDMO市場規模
イギリスの先進的治療薬CDMO市場規模
ドイツの先進的治療薬CDMO市場規模
フランスの先進的治療薬CDMO市場規模
ロシアの先進的治療薬CDMO市場規模

- その他地域の先進的治療薬CDMO市場規模

・競争状況
・企業情報

The Global Advanced Therapy Medicinal Products CDMO Market size was estimated at USD 5,452.88 million in 2021 and expected to reach USD 6,292.62 million in 2022, and is projected to grow at a CAGR 15.65% to reach USD 13,050.03 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Advanced Therapy Medicinal Products CDMO to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Products, the market was studied across Cell Therapy, Gene Therapy, and Tissue Engineered.

Based on Phase, the market was studied across Phase I, Phase II, Phase III, and Phase IV.

Based on Indication, the market was studied across Cardiology, Central Nervous System, Dermatology, Endocrine, Metabolic, Genetic, Gastroenterology, Hematology, Immunology & Inflammation, Infectious Disease, Musculoskeletal, Oncology, and Ophthalmology.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Advanced Therapy Medicinal Products CDMO market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Advanced Therapy Medicinal Products CDMO Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Advanced Therapy Medicinal Products CDMO Market, including Advanced Therapies, Inc., AGC Inc., Almac Group, Arranta Bio, Bio Elpida, Catalent Inc., Cell and Gene Therapy Catapult Limited, Celonic AG, Charles River Laboratories, Cobra Biologics Limited, Coriolis Pharma Research GmbH, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Patheon, Rentschler Biopharma SE, RoslinCT, and Stempeutics Research Pvt. Ltd..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Advanced Therapy Medicinal Products CDMO Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Advanced Therapy Medicinal Products CDMO Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Advanced Therapy Medicinal Products CDMO Market?
4. What is the competitive strategic window for opportunities in the Global Advanced Therapy Medicinal Products CDMO Market?
5. What are the technology trends and regulatory frameworks in the Global Advanced Therapy Medicinal Products CDMO Market?
6. What is the market share of the leading vendors in the Global Advanced Therapy Medicinal Products CDMO Market?
7. What modes and strategic moves are considered suitable for entering the Global Advanced Therapy Medicinal Products CDMO Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising numbers of clinical trials for development of advanced therapy medicinal products
5.1.1.2. Increasing investments in pharmaceutical research and development worldwide
5.1.1.3. Proliferation in prevalence of rare diseases with growing emergence of novel infectious diseases
5.1.2. Restraints
5.1.2.1. High cost associated with outsourcing ATMP solutions
5.1.3. Opportunities
5.1.3.1. Surging number of advanced therapy medicinal products CDMOs coupled with technological advancements in existing product portfolios
5.1.3.2. Favorable governmental initiatives and investments for clinical trials with surge in number of government approvals for ATMP
5.1.4. Challenges
5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and commercialization
5.2. Cumulative Impact of COVID-19

6. Advanced Therapy Medicinal Products CDMO Market, by Products
6.1. Introduction
6.2. Cell Therapy
6.3. Gene Therapy
6.4. Tissue Engineered

7. Advanced Therapy Medicinal Products CDMO Market, by Phase
7.1. Introduction
7.2. Phase I
7.3. Phase II
7.4. Phase III
7.5. Phase IV

8. Advanced Therapy Medicinal Products CDMO Market, by Indication
8.1. Introduction
8.2. Cardiology
8.3. Central Nervous System
8.4. Dermatology
8.5. Endocrine, Metabolic, Genetic
8.6. Gastroenterology
8.7. Hematology
8.8. Immunology & Inflammation
8.9. Infectious Disease
8.10. Musculoskeletal
8.11. Oncology
8.12. Ophthalmology

9. Americas Advanced Therapy Medicinal Products CDMO Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Advanced Therapies, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AGC Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Almac Group
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Arranta Bio
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bio Elpida
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Catalent Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Cell and Gene Therapy Catapult Limited
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Celonic AG
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Charles River Laboratories
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Cobra Biologics Limited
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Coriolis Pharma Research GmbH
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. FUJIFILM Corporation
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Lonza Group
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Minaris Regenerative Medicine
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Patheon
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Rentschler Biopharma SE
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. RoslinCT
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Stempeutics Research Pvt. Ltd.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing




• 英文レポート名:Advanced Therapy Medicinal Products CDMO Market Research Report by Products, Phase, Indication, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
• 日本語訳:先進的治療薬CDMOの世界市場予測(~2027年)
• レポートコード:MRC2301B088お問い合わせ(見積依頼・ご注文・質問)